Prosecution Insights
Last updated: April 19, 2026

Examiner: TURPIN, ZACHARY MARK

Tech Center 1600 • Art Units: 1682

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
72
Total Applications
+0.0%
Interview Lift
1175
Avg Prosecution Days
Based on 11 resolved cases, 2023–2026

Rejection Statute Breakdown

9.0%
§101 Eligibility
19.7%
§102 Novelty
30.8%
§103 Obviousness
25.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17826091 FLOW CELLS AND METHODS Final Rejection ILLUMINA, INC.
18033754 TRANSCRIPTOMICS WITH ELECTROPHYSIOLOGICAL RECORDING Non-Final OA President and Fellows of Harvard College
17770943 GENOME-SCALE IMAGING OF THE 3D ORGANIZATION AND TRANSCRIPTIONAL ACTIVITY OF CHROMATIN Final Rejection President and Fellows of Harvard College
18364849 COMPETITIVE METHODS AND COMPOSITIONS FOR AMPLIFYING POLYNUCLEOTIDES Non-Final OA Singular Genomics Systems, Inc.
18496492 METHODS, COMPOSITIONS, AND SYSTEMS FOR SPATIAL ANALYSIS OF BIOLOGICAL SAMPLES Non-Final OA 10x Genomics, Inc.
18365684 SYSTEMS AND METHODS FOR IMMUNOFLUORESCENCE QUANTIFICATION Non-Final OA 10x Genomics, Inc.
17819472 METHOD FOR EARLY DETERMINATION OF GENDER BY MULTIPLEX PCR DETECTING FOUR GENES Non-Final OA King Saud University
17416399 RATIOMETRIC FLUORESCENCE CODING METHOD FOR MULTIPLEX NUCLEIC ACID AMPLIFICATION ASSAYS Non-Final OA The Johns Hopkins University
18033054 METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS Non-Final OA PRELUDE CORPORATION
17550262 METHODS, SYSTEMS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING Final Rejection Illumina Cambridge Limited
18494528 COMPOSITIONS AND METHODS FOR CHARACTERIZING POLYNUCLEOTIDE SEQUENCE ALTERATIONS Non-Final OA The Brigham and Women's Hospital, Inc.
17751952 SPATIAL SEQUENCING WITH MICTAG Final Rejection Miltenyi Biotec B.V. & Co. KG
18024488 METHODS FOR EARLY DETECTION OF BREAST CANCER Non-Final OA THE TRUSTEES OF INDIANA UNIVERSITY
17791706 TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS Non-Final OA H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18495414 ADRM1/RPN13 SPLICED VARIANT IN THE PROGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA Non-Final OA The Chinese University of Hong Kong
18038381 Targeted enrichment using nanopore selective sequencing Non-Final OA KEYGENE N.V.
18247474 RAPID DIAGNOSTIC ELECTROCHEMICAL BIOSENSING TARGETED WITH ANTISENSE OLIGONUCLEOTIDES Non-Final OA University of Maryland, Baltimore County
18022844 Methods and Compositions For Preparing Nucleic Acids For Genetic Analysis Final Rejection Takara Bio USA, Inc.
18281930 METHODS FOR SEQUENCING NUCLEIC ACID MOLECULES WITH SEQUENTIAL BARCODES Non-Final OA Ultima Genomics, Inc.
17459459 DETECTING ELEMENTS USING SUGAR-LECTIN COUPLINGS Final Rejection ILLUMINA SINGAPORE PTE. LTD.
17616279 KIT AND METHOD FOR ANALYZING SINGLE T CELLS Non-Final OA ST. JUDE CHILDREN'S RESEARCH HOSPITAL
17783365 HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE Final Rejection SUZHOU SMK GENE TECH LTD.
17779439 DETECTION AND ELIMINATION OF ABERRANT CELLS Final Rejection Viome Life Sciences, Inc.
17771793 HLA-H, HLA-J, HLA-L, HLA-V AND HLA-Y AS THERAPEUTIC AND DIAGNOSTIC TARGETS Final Rejection Intellexon GmbH
17693222 Targeted Sequence Detection by Nanopore Sensing of Synthetic Probes Final Rejection Nooma Bio, Inc.
17631074 TUMOUR MARKER AND USE THEREOF Final Rejection Lisen Imprinting Diagnostics Wuxi Co., Ltd.
17628006 DIFFERENTIATION MARKER GENE SET, METHOD, AND KIT FOR DIFFERENTIATING OR CLASSIFYING SUBTYPE OF BREAST CANCER Non-Final OA PUBLIC UNIVERSITY CORPORATION FUKUSHIMA MEDICAL UNIVERSITY
17618239 METHODS AND COMPOSITIONS FOR LUNG CANCER DETECTION Final Rejection SUZHOU HOHO HEALTH CO., LTD.
17607490 METHODS AND REAGENTS FOR NUCLEIC ACID SEQUENCING AND ASSOCIATED APPLICATIONS Non-Final OA TwinStrand Biosciences, Inc.
17603439 METHOD FOR DETECTING SPECIFIC NUCLEIC ACIDS IN SAMPLES Final Rejection GenePath Diagnostics Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month